SG11202104912SA - Fusion protein and use thereof - Google Patents

Fusion protein and use thereof

Info

Publication number
SG11202104912SA
SG11202104912SA SG11202104912SA SG11202104912SA SG11202104912SA SG 11202104912S A SG11202104912S A SG 11202104912SA SG 11202104912S A SG11202104912S A SG 11202104912SA SG 11202104912S A SG11202104912S A SG 11202104912SA SG 11202104912S A SG11202104912S A SG 11202104912SA
Authority
SG
Singapore
Prior art keywords
fusion protein
fusion
protein
Prior art date
Application number
SG11202104912SA
Inventor
Ming Lv
Xiaoran Ding
Shiwei Miao
Bin Tan
Xuegong Wang
Original Assignee
Hangzhou Sumgen Biotech Co Ltd
Sumgen Mab Beijing Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Sumgen Biotech Co Ltd, Sumgen Mab Beijing Biotech Co Ltd filed Critical Hangzhou Sumgen Biotech Co Ltd
Publication of SG11202104912SA publication Critical patent/SG11202104912SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
SG11202104912SA 2018-11-14 2019-11-13 Fusion protein and use thereof SG11202104912SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811356690.9A CN111303293B (en) 2018-11-14 2018-11-14 Fusion protein and application thereof
PCT/CN2019/117856 WO2020098672A1 (en) 2018-11-14 2019-11-13 Fusion protein and use thereof

Publications (1)

Publication Number Publication Date
SG11202104912SA true SG11202104912SA (en) 2021-06-29

Family

ID=70731941

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104912SA SG11202104912SA (en) 2018-11-14 2019-11-13 Fusion protein and use thereof

Country Status (11)

Country Link
US (1) US20210317230A1 (en)
EP (1) EP3882277A4 (en)
JP (1) JP2022513008A (en)
KR (1) KR20210093265A (en)
CN (2) CN111303293B (en)
AU (1) AU2019379207A1 (en)
BR (1) BR112021009366A2 (en)
CA (1) CA3119400A1 (en)
SG (1) SG11202104912SA (en)
TW (1) TW202031687A (en)
WO (1) WO2020098672A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110540592B (en) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 Antibodies that bind to AXL protein and uses thereof
KR20230088370A (en) * 2020-09-18 2023-06-19 아이크노스 사이언스 에스. 아. CD47-CD38 bispecific antibody
CN116178561A (en) * 2021-11-26 2023-05-30 杭州尚健生物技术有限公司 Fusion proteins comprising SIRPalpha mutants
CN116143902A (en) * 2021-11-19 2023-05-23 杭州尚健生物技术有限公司 SIRP alpha variants and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
DK1483294T3 (en) * 2002-03-01 2010-11-08 Immunomedics Inc Internalizing anti-CD74 antibodies and methods for their use
CA2957531A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Sirp alpha-antibody fusion proteins
CA2956126A1 (en) * 2014-08-15 2016-02-18 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
IL294679B2 (en) * 2015-08-07 2023-10-01 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof

Also Published As

Publication number Publication date
CN111303293A (en) 2020-06-19
EP3882277A1 (en) 2021-09-22
CN113015751A (en) 2021-06-22
AU2019379207A1 (en) 2021-06-10
US20210317230A1 (en) 2021-10-14
WO2020098672A1 (en) 2020-05-22
CN111303293B (en) 2022-08-30
KR20210093265A (en) 2021-07-27
EP3882277A4 (en) 2022-08-03
JP2022513008A (en) 2022-02-07
BR112021009366A2 (en) 2021-08-17
TW202031687A (en) 2020-09-01
CA3119400A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
IL279510A (en) Progranulin-fc polypeptide fusion proteins and uses thereof
KR102201086B9 (en) Il-2 cd80 fusion protein comprising il-2 protein and cd80 protein and use thereof
SG11202012004SA (en) Rna-targeting fusion protein compositions and methods for use
IL280102A (en) Pd1-4-1bbl variant fusion protein and methods of use thereof
IL267861A (en) A pd1-41bbl fusion protein and methods of use thereof
IL279505A (en) Chimeric transmembrane proteins and uses thereof
IL267862A (en) A sirpalpha-41bbl fusion protein and methods of use thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
GB2570063B (en) Fusion protein and applications thereof
EP3722305A4 (en) Hm-3 fusion protein and use thereof
SG11202104912SA (en) Fusion protein and use thereof
IL280103A (en) Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
SG11202110400QA (en) Fusion protein and use thereof
ZA202000595B (en) Novel therapeutic enzyme fusion protein and use thereof
ZA202101250B (en) Novel crispr-associated protein and use thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL282708A (en) Anti-tim-3 antibodies and their use
EP3668551A4 (en) Apom-fc fusion proteins and uses thereof
ZA202100092B (en) Modified cas9 protein and use thereof
IL279057A (en) Endolysin-containing antimicrobial fusion proteins and uses thereof
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
GB201819200D0 (en) Polypeptide and uses thereof
EP3816181A4 (en) Improved fviii fusion protein and use thereof
ZA202102533B (en) Fusion protein
GB202201004D0 (en) Reconbinant fusion polypeptide and use thereof